139 related articles for article (PubMed ID: 31235865)
1. Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression.
Berndsen RH; Castrogiovanni C; Weiss A; Rausch M; Dallinga MG; Miljkovic-Licina M; Klaassen I; Meraldi P; van Beijnum JR; Nowak-Sliwinska P
Br J Cancer; 2019 Jul; 121(2):139-149. PubMed ID: 31235865
[TBL] [Abstract][Full Text] [Related]
2. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.
Mathias TJ; Natarajan K; Shukla S; Doshi KA; Singh ZN; Ambudkar SV; Baer MR
Invest New Drugs; 2015 Apr; 33(2):300-9. PubMed ID: 25597754
[TBL] [Abstract][Full Text] [Related]
3. Effects of crenolanib, a nonselective inhibitor of PDGFR, in a mouse model of transient middle cerebral artery occlusion.
Wang J; Fu X; Zhang D; Yu L; Lu Z; Gao Y; Liu X; Man J; Li S; Li N; Wang M; Liu X; Chen X; Zang W; Yang Q; Wang J
Neuroscience; 2017 Nov; 364():202-211. PubMed ID: 28943249
[TBL] [Abstract][Full Text] [Related]
4. Crenolanib is a selective type I pan-FLT3 inhibitor.
Smith CC; Lasater EA; Lin KC; Wang Q; McCreery MQ; Stewart WK; Damon LE; Perl AE; Jeschke GR; Sugita M; Carroll M; Kogan SC; Kuriyan J; Shah NP
Proc Natl Acad Sci U S A; 2014 Apr; 111(14):5319-24. PubMed ID: 24623852
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
[TBL] [Abstract][Full Text] [Related]
6. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo.
Wang P; Song L; Ge H; Jin P; Jiang Y; Hu W; Geng N
Onco Targets Ther; 2014; 7():1761-8. PubMed ID: 25328409
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells.
Andrae N; Kirches E; Hartig R; Haase D; Keilhoff G; Kalinski T; Mawrin C
Eur J Cancer; 2012 Aug; 48(12):1831-41. PubMed ID: 22391574
[TBL] [Abstract][Full Text] [Related]
8. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
9. Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
Mahboobi S; Uecker A; Sellmer A; Cénac C; Höcher H; Pongratz H; Eichhorn E; Hufsky H; Trümpler A; Sicker M; Heidel F; Fischer T; Stocking C; Elz S; Böhmer FD; Dove S
J Med Chem; 2006 Jun; 49(11):3101-15. PubMed ID: 16722630
[TBL] [Abstract][Full Text] [Related]
10. Crenolanib-Derived Probes Suitable for Cell- and Tissue-Based Protein Profiling and Single-Cell Imaging.
Chang Y; Zhu D; Guo H; Yin X; Ding K; Li Z
Chembiochem; 2019 Jul; 20(14):1783-1788. PubMed ID: 30942519
[TBL] [Abstract][Full Text] [Related]
11. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
12. Insight into the inhibitor discrimination by FLT3 F691L.
Verma S; Singh A; Kumari A; Pandey B; Jamal S; Goyal S; Sinha S; Grover A
Chem Biol Drug Des; 2018 May; 91(5):1056-1064. PubMed ID: 29336115
[TBL] [Abstract][Full Text] [Related]
13. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
[TBL] [Abstract][Full Text] [Related]
14. Arsenite suppresses angiogenesis of vascular endothelial cells mediated by Platelet Derived Growth Factor Receptor-beta.
Wang X; Mou Y; Yue Z; Zhang H; Su X; Wang Y; Li R; Sun X
Environ Toxicol Pharmacol; 2016 Sep; 46():168-173. PubMed ID: 27475902
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
[TBL] [Abstract][Full Text] [Related]
16. Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.
Makino K; Makino T; Stawski L; Mantero JC; Lafyatis R; Simms R; Trojanowska M
J Invest Dermatol; 2017 Aug; 137(8):1671-1681. PubMed ID: 28433542
[TBL] [Abstract][Full Text] [Related]
17. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
18. Epoxyquinol B shows antiangiogenic and antitumor effects by inhibiting VEGFR2, EGFR, FGFR, and PDGFR.
Kamiyama H; Kakeya H; Usui T; Nishikawa K; Shoji M; Hayashi Y; Osada H
Oncol Res; 2008; 17(1):11-21. PubMed ID: 18488711
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
Matei D; Chang DD; Jeng MH
Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
[TBL] [Abstract][Full Text] [Related]
20. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
